CureMeAbroad Raises $1.1M Pre-Seed to Expand Medical Tourism Platform

Pune-based healthcare technology startup CureMeAbroad has raised $1.1 million in a pre-seed funding round to expand its medical tourism platform, grow its international hospital network and enter new patient markets.

The round was led by healthcare-focused venture capital fund SteerX Ventures, with existing investor AIRA also participating. The fresh capital comes several months after CureMeAbroad raised $600,000 from a group of individual investors and AIRA.

Founded in June 2025 by Aditya Oza and Mikhail Bohra, CureMeAbroad helps international patients discover hospitals, compare treatment options, verify healthcare providers, understand treatment costs and book medical care across countries.

The company plans to use the new funding to expand its accredited hospital network, enter additional patient source markets, strengthen its AI-powered technology and grow its operations and technology teams.

Building a platform for international healthcare

Medical tourism can involve a complicated series of decisions for patients travelling outside their home country for treatment.

Patients need to identify suitable hospitals, understand whether providers are properly accredited, compare treatment options and estimate costs before making arrangements to travel. They may also need assistance with booking and planning the treatment itself.

CureMeAbroad is positioning its platform as a single point for these stages of the journey.

The company allows international patients to discover and compare hospitals, verify healthcare providers, obtain treatment estimates and book care across different destinations.

Its platform combines healthcare discovery with treatment planning, pricing information and patient assistance.

The startup currently attracts more than 22,500 visitors each month and has built a hospital network spanning six countries.

According to the company, its key patient source markets include the United States, United Kingdom, Australia and Canada.

$1.1M funding follows earlier investment

The latest $1.1 million round was led by SteerX Ventures, a healthcare-focused venture capital fund. Existing investor AIRA also participated.

The investment follows a $600,000 round raised by CureMeAbroad in April 2026. That earlier funding included investments from Roman Saini, Himanshu Ratnoo, Kunal Gupta, Devaiah Bopanna, Vikrant Potnis and AIRA.

Together, the two rounds give CureMeAbroad additional capital to build out its platform while expanding its network of hospitals and international patient markets.

The company has not disclosed a valuation as part of the latest financing.

Its immediate focus is on expanding the supply side of its platform by adding more accredited hospitals while also reaching patients in additional international markets.

Expanding beyond elective treatments

CureMeAbroad currently operates across multiple treatment destinations, but its next phase includes expansion into non-elective specialties.

The company plans to enter areas such as orthopaedics and oncology.

These specialties could broaden the type of international healthcare journeys supported through its platform, although they also involve more complex treatment decisions and patient requirements.

CureMeAbroad is also exploring physical experience centres in key international markets.

The proposed centres could complement its digital platform by providing patients with an offline point of assistance during the medical tourism process.

The company is also investing in its AI-powered technology. The funding will be used to strengthen the technology platform alongside hiring across operations and technology.

Aiming for $100M in patient bookings

CureMeAbroad says it is targeting $100 million in annual patient treatment bookings by FY2028.

That compares with a current run rate of $4.8 million, meaning the company is targeting a substantial increase in the value of treatments booked through its platform over the next few years.

The company already attracts more than 22,500 monthly visitors, providing an existing base from which it can try to increase patient conversions.

Its international focus is also reflected in its source markets. Patients currently come primarily from the US, UK, Australia and Canada.

For a medical tourism platform, expanding traffic is only one part of the equation. The company also needs to convert patients into treatment bookings, maintain relationships with hospitals and build confidence around provider quality, pricing and treatment planning.

That makes the expansion of its accredited hospital network particularly important to the company's growth strategy.

Competing in a growing medical tourism market

CureMeAbroad is entering a market that already includes several established international healthcare discovery and medical tourism platforms.

Its competitors include Bookimed, PlacidWay, The Medical Tourism Company and Medical Departures.

India also has domestic players serving international patients. Vaidam Health, for example, helps overseas patients discover hospitals and treatment options in India.

CureMeAbroad is differentiating itself through a combination of hospital discovery, provider verification, treatment estimates, booking and patient assistance.

The company has also received Medical Travel Facilitator Certification from Global Healthcare Accreditation. According to GHA, its network includes more than 400 accredited hospitals across six countries.

That accreditation and hospital network could be important as the company attempts to build trust among patients considering treatment outside their home countries.

The role of AI in medical tourism

CureMeAbroad is also using AI as part of its technology strategy.

For patients, medical tourism can involve comparing providers, treatments, destinations and costs across multiple variables. A technology layer that can organize and personalize this information could potentially make the discovery and planning process easier.

The company plans to invest further in its AI-powered platform with the latest funding.

However, healthcare remains a high-trust category. Patients making treatment decisions need reliable information, qualified providers and clear communication, meaning technology alone is unlikely to replace the role of accredited hospitals and healthcare professionals.

For CureMeAbroad, the challenge will be to use technology to simplify the patient journey while maintaining confidence in the underlying healthcare network.

What comes next for CureMeAbroad?

The new funding gives CureMeAbroad room to expand across both sides of its marketplace.

On the supply side, it plans to add more accredited hospitals and expand its network beyond the six countries it currently covers.

On the demand side, it plans to enter new patient source markets and grow its presence among international patients, particularly across markets such as the US, UK, Australia and Canada.

The company also intends to expand its treatment categories, strengthen its AI technology and build its operations and technology teams.

Its $100 million FY2028 patient-booking target sets an ambitious growth benchmark. Reaching that level would require significant growth from its current $4.8 million run rate.

For now, CureMeAbroad is using its $1.1 million pre-seed round to build the infrastructure needed for that expansion, combining hospital accreditation, healthcare discovery, treatment planning and patient support in a single medical tourism platform.